296 related articles for article (PubMed ID: 18381962)
41. The role of HER-2 oncoprotein in drug-sensitivity in breast cancer (review).
Kim R; Tanabe K; Uchida Y; Osaki A; Toge T
Oncol Rep; 2002; 9(1):3-9. PubMed ID: 11748447
[TBL] [Abstract][Full Text] [Related]
42. HER3 is a determinant for poor prognosis in melanoma.
Reschke M; Mihic-Probst D; van der Horst EH; Knyazev P; Wild PJ; Hutterer M; Meyer S; Dummer R; Moch H; Ullrich A
Clin Cancer Res; 2008 Aug; 14(16):5188-97. PubMed ID: 18698037
[TBL] [Abstract][Full Text] [Related]
43. Overexpression of caspase-3s splice variant in locally advanced breast carcinoma is associated with poor response to neoadjuvant chemotherapy.
Végran F; Boidot R; Oudin C; Riedinger JM; Bonnetain F; Lizard-Nacol S
Clin Cancer Res; 2006 Oct; 12(19):5794-800. PubMed ID: 17020986
[TBL] [Abstract][Full Text] [Related]
44. Altered expression of cyclin E and the retinoblastoma protein influences the effect of adjuvant therapy in breast cancer.
Waltersson MA; Askmalm MS; Nordenskjöld B; Fornander T; Skoog L; Stål O
Int J Oncol; 2009 Feb; 34(2):441-8. PubMed ID: 19148479
[TBL] [Abstract][Full Text] [Related]
45. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
[TBL] [Abstract][Full Text] [Related]
46. EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer.
Nogi H; Kobayashi T; Suzuki M; Tabei I; Kawase K; Toriumi Y; Fukushima H; Uchida K
Oncol Rep; 2009 Feb; 21(2):413-7. PubMed ID: 19148516
[TBL] [Abstract][Full Text] [Related]
47. A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial.
Jézéquel P; Campone M; Roché H; Gouraud W; Charbonnel C; Ricolleau G; Magrangeas F; Minvielle S; Genève J; Martin AL; Bataille R; Campion L
Breast Cancer Res Treat; 2009 Aug; 116(3):509-20. PubMed ID: 19020972
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling.
Ischenko I; Camaj P; Seeliger H; Kleespies A; Guba M; De Toni EN; Schwarz B; Graeb C; Eichhorn ME; Jauch KW; Bruns CJ
Oncogene; 2008 Dec; 27(57):7212-22. PubMed ID: 18794807
[TBL] [Abstract][Full Text] [Related]
49. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.
Gianni L; Baselga J; Eiermann W; Porta VG; Semiglazov V; Lluch A; Zambetti M; Sabadell D; Raab G; Cussac AL; Bozhok A; Martinez-Agulló A; Greco M; Byakhov M; Lopez JJ; Mansutti M; Valagussa P; Bonadonna G
J Clin Oncol; 2009 May; 27(15):2474-81. PubMed ID: 19332727
[TBL] [Abstract][Full Text] [Related]
50. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.
Bertheau P; Turpin E; Rickman DS; Espié M; de Reyniès A; Feugeas JP; Plassa LF; Soliman H; Varna M; de Roquancourt A; Lehmann-Che J; Beuzard Y; Marty M; Misset JL; Janin A; de Thé H
PLoS Med; 2007 Mar; 4(3):e90. PubMed ID: 17388661
[TBL] [Abstract][Full Text] [Related]
51. Prevalence and prognostic and predictive relevance of PRAME in breast cancer.
Doolan P; Clynes M; Kennedy S; Mehta JP; Crown J; O'Driscoll L
Breast Cancer Res Treat; 2008 May; 109(2):359-65. PubMed ID: 17624586
[TBL] [Abstract][Full Text] [Related]
52. Functional sodium iodide symporter expression in breast cancer xenografts in vivo after systemic treatment with retinoic acid and dexamethasone.
Willhauck MJ; Sharif-Samani B; Senekowitsch-Schmidtke R; Wunderlich N; Göke B; Morris JC; Spitzweg C
Breast Cancer Res Treat; 2008 May; 109(2):263-72. PubMed ID: 17636401
[TBL] [Abstract][Full Text] [Related]
53. Prognostic impact of orotate phosphoribosyl transferase activity in resectable colorectal cancers treated by 5-fluorouracil-based adjuvant chemotherapy.
Ochiai T; Nishimura K; Noguchi H; Kitajima M; Tsuruoka Y; Takahashi Y; Tsukada A; Watanabe E; Nagaoka I; Futagawa S
J Surg Oncol; 2006 Jul; 94(1):45-50. PubMed ID: 16788943
[TBL] [Abstract][Full Text] [Related]
54. E2F1 expression is related with the poor survival of lymph node-positive breast cancer patients treated with fluorouracil, doxorubicin and cyclophosphamide.
Han S; Park K; Bae BN; Kim KH; Kim HJ; Kim YD; Kim HY
Breast Cancer Res Treat; 2003 Nov; 82(1):11-6. PubMed ID: 14672398
[TBL] [Abstract][Full Text] [Related]
55. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P
Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635
[TBL] [Abstract][Full Text] [Related]
56. Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy.
Vincent-Salomon A; Rousseau A; Jouve M; Beuzeboc P; Sigal-Zafrani B; Fréneaux P; Rosty C; Nos C; Campana F; Klijanienko J; Al Ghuzlan A; Sastre-Garau X;
Eur J Cancer; 2004 Jul; 40(10):1502-8. PubMed ID: 15196533
[TBL] [Abstract][Full Text] [Related]
57. Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients.
Jansson A; Delander L; Gunnarsson C; Fornander T; Skoog L; Nordenskjöld B; Stål O
Clin Cancer Res; 2009 May; 15(10):3610-6. PubMed ID: 19401349
[TBL] [Abstract][Full Text] [Related]
58. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity.
Müller V; Stahmann N; Riethdorf S; Rau T; Zabel T; Goetz A; Jänicke F; Pantel K
Clin Cancer Res; 2005 May; 11(10):3678-85. PubMed ID: 15897564
[TBL] [Abstract][Full Text] [Related]
59. Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.
Johansson P; Fohlin H; Arnesson LG; Dufmats M; Nordenskjöld K; Nordenskjöld B; Stål O;
Acta Oncol; 2009; 48(4):504-13. PubMed ID: 19235568
[TBL] [Abstract][Full Text] [Related]
60. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
